PRA teams with CISCRP for trial result summaries
PRA Health Sciences is collaborating with CISCRP to provide patients with soon to be mandatory clinical trial result summaries.
Archives for February 26, 2019
Icon nabs molecular diagnostic lab to support precision medicine programs
Icon acquired the molecular diagnostic laboratory MolecularMD to further support precision medicine programs across all development phases.
Wilmington PharmaTech invests $18m in new research, manufacturing facility
The DE-based CDMO plans to hire up to 139 new employees as part of an $18m investment into a new research and manufacturing facility.
FDA review gives Virpax go-ahead for pain relief candidates
A pre-IND review by the US FDA has allowed Virpax to continue with NDAs for DSF100 and LBL100, two pain relief products with specialised drug delivery formulations.
Round-up: Innovations and developments in drug delivery
Innovations in drug delivery have hit the market running and as complex drugs breaking onto the market while delivery systems and technologies follow.
Drug delivery manufacturing evolves to keep up with intricate therapies
A drug is only as effective as its delivery system, and the advent of new molecules and new innovations have to be matched by enhanced delivery and containment methods, suggests West Pharma exec.
Global injectable drug delivery market to double by 2025 to $932m
A report suggests that the global injectable drug delivery market will expand at a CAGR of 11.2% between 2019 and 2025.
Ipsen adds to rare disease portfolio with $1.3bn Clementia deal
Ipsen acquires Clementia and takes on late-stage clinical asset for the treatment of rare bone disorders, in its largest transaction to date.
Sanofi manufactures radiotherapy nanoparticles
Sanofi agrees to produce French start-ups’ nanoparticle drug candidate indicated for the maximization of radiotherapy at its French site.
Altasciences eyes early development space, CDMO addition
Consolidating its businesses under one brand, Altasciences is transitioning to an early drug development CRO – and looking to add a CDMO to manufacture drugs up to Phase II volumes.